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ABSTRACT
We previously demonstrated that proto-oncogene Fyn decreased energy 
expenditure and increased metabolic phenotypes. Also Fyn decreased autophagy-
mediated muscle mass by directly inhibiting LKB1 and stimulating STAT3 activities, 
respectively. AMPK, a downstream target of LKB1, was recently identified as a key 
molecule controlling autophagy. Here we identified that Fyn phosphorylates the α 
subunit of AMPK on Y436 and inhibits AMPK enzymatic activity without altering the 
assembly state of the AMPK heterotrimeric complex. As pro-inflammatory mediators 
are reported modulators of the autophagy processes, treatment with the pro-
inflammatory cytokine TNFα resulted in 1) increased Fyn activity 2) stimulated Fyn-
dependent AMPKα tyrosine phosphorylation and 3) decreased AICAR-dependent AMPK 
activation. Importantly, TNFα induced inhibition of autophagy was not observed when 
AMPKα was mutated on Y436. 4) These data demonstrate that Fyn plays an important 
role in relaying the effects of TNFα on autophagy and apoptosis via phosphorylation 
and inhibition of AMPK.
INTRODUCTION
Although autophagy is originally described as an 
evolutionarily conserved cellular recycling program [1, 2], 
recent studies have demonstrated the role of autophagy 
in metabolic functions. Indeed autophagy participates 
in hepatic lipid storage [3], glucose homeostasis [4, 
5], adipocyte differentiation [6, 7] and protects α 
cells against chronic lipid stress [8, 9]. Interestingly, 
deregulation of these functions is also associated with 
inflammatory processes, suggesting that inflammatory 
molecules modulate the autophagy function. In line 
with this, prolonged exposure of tissues and organs to 
high concentrations of inflammatory mediators inhibits 
autophagy response, resulting in severe cell damage and 
apoptosis [10, 11]. 
The molecular mechanisms underlining the cross 
talk between autophagy processes, energy metabolism 
and immune function have been under scrutiny. Recently, 
molecules traditionally known for their role in metabolism 
and homeostasis have been identified as elements of the 
autophagy pathway. Amongst them is the AMP-dependent 
protein kinase [AMPK], one of the major energy sensors 
of the cell [1, 12, 13]. AMPK is a highly conserved 
heterotrimeric complex composed of three subunits α, β 
and γ [14-16]. AMP binds to the γ subunit and increases 
the phosphorylation of the catalytic α subunit T172 residue 
by upstream kinases such as Ca2+/calmodulin-dependent 
protein kinase kinase (CaMKK2) in the brain and Liver 
Kinase B1 (LKB1) in peripheral organs [17, 18], resulting 
in the activation of AMPK kinase. The relative expression 
levels, association, and subcellular distribution of these 
upstream kinases in addition to the expression levels of the 
various AMPK α, β, γ subunit isoforms are responsible for 
the large pleiotropic responses of AMPK under a variety 
of cellular states [19]. 
Although the link between AMPK and autophagy 
is established, upstream regulators of AMPK in the 
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context of autophagy response are still largely unknown. 
Previously, we reported that Fyn knockout (FynKO) 
mice display increased AMPK activity as a result of Fyn-
dependent LKB1 regulation in peripheral tissues [20, 
21]. Another recent publication also demonstrates that 
Fyn exerts its inhibitory effect on AMPK through both 
LKB1 and PIKE-A pathways [22]. Fyn is a member of 
the Src family of proto-oncogene non-receptor tyrosine 
kinases with multiple functions including the regulation 
of several inflammatory processes [23, 24]. Two major 
spliced isoforms, FynB and FynT have been reported [25], 
differing by their kinase activity (Fyn T being the most 
active isoform) and functions [26]. Interestingly, using 
muscle specific FynB or FynT over-expressing animals 
we recently demonstrated Fyn-dependent inhibition of 
autophagy via STAT3 regulation in muscle [27]. Although 
this pathway accounts for the ability of Fyn to suppress 
autophagy under basal conditions, other signalling events 
are likely to be involved under pathological conditions, 
particularly under metabolic stress, a condition associated 
with increased inflammatory processes and production 
of metabolic cytokines such as TNFα [28]. Interestingly, 
studies show that TNFα inhibits autophagy processes [10, 
29] and others suggest that TNFα regulates AMPK activity 
[28, 30-32]. Yet, it has not been fully examined whether 
TNFα inhibits autophagy through AMPK.
In this study, we demonstrate that 1) Fyn specifically 
phosphorylates AMPKα on Y436, resulting in AMPK 
activity inhibition and thereby suppressing autophagy, 
2) TNFα activates Fyn kinase, 3) Fyn deficiency blocks 
TNFα inhibition of autophagy by preventing AMPK α 
subunit Y436 phosphorylation and 4) Fyn deficiency 
protects against TNFα activation of apoptosis. 
RESULTS
AMPK undergoes Fyn-dependent tyrosine 
phosphorylation
Having recently identified LKB1 and STAT3 as 
direct substrates of Fyn in the respective regulation of 
metabolism [21] and muscle autophagy [27], we wished 
to identify other potential Fyn targets. Skeletal muscle 
extracts from Fyn over-expressing and FynKO mice 
were subjected to mass spectrometry analysis [27]. Along 
with the increased STAT3 Y705 phosphorylation in Fyn 
over-expressing mice, we also found a marked increase 
in phosphorylation on Y436 of the AMPK α subunit 
(Supplementary Figure 1A, 1B), suggesting that Y436 
could be a specific site for Fyn. 
To confirm Fyn-dependent tyrosine phosphorylation 
of AMPK, gastrocnemius muscle tissue extracts were 
prepared from Fyn knockout (FynKO), wild type (WT), 
skeletal muscle-specific over expressing FynB and FynT 
mice. The extracts were immunoblotted for AMPK α 
subunit and GADPH as a loading control (Figure 1A). 
Immunoprecipitation of these extracts with the 4G10 
phospho-tyrosine specific antibody demonstrated a low 
level of AMPK tyrosine phosphorylation in the FynKO 
mice compared to control WT mice (Figure 1B). In 
contrast, skeletal muscle extracts from the FynB and FynT 
overexpressing mice displayed an approximate 2-fold 
increase in AMPK α subunit tyrosine phosphorylation 
compared to wild type mice. FynT is the most active 
isoform of Fyn, yet AMPKα phosphorylation levels 
in FynT mice were similar to those seen in FynB mice. 
However, we found that total AMPKα expression (Figure 
1A) in FynT muscle was decreased compared to WT, 
FynKO or FynB mice, likely due to the fact that FynT 
mice display a strong sarcopenic phenotype [27] known 
to decrease AMPKα expression [28, 33]. Therefore, when 
normalized to total AMPKα, protein levels, tyrosine 
phosphorylation of AMPKα in FynT mice was further 
increased when compared to FynB mice (Figure 1C).
To determine if Fyn phosphorylates the AMPKα 
in cell culture conditions, we co-expressed an epitope 
tagged AMPKα2 (AMPKα2-Flag) cDNA with or without 
an epitope tagged constitutively active Fyn (V5-Fyn-CA) 
cDNA in NIH-3T3 cells (Figure 2A). Expression of V5-
Fyn-CA resulted in the robust tyrosine phosphorylation 
levels of AMPKα2-Flag (Figure 2B). We recently reported 
that Fyn directly phosphorylates LKB1 to modulate 
AMPK activity [21]. To evaluate whether AMPK tyrosine 
phosphorylation is also dependent on LKB1, we co-
expressed LKB1 in HEK293T cells. LKB1 had no effect 
on V5-Fyn-CA or AMPKα2-Flag expression. Importantly, 
tyrosine phosphorylation of AMPKα2-Flag in presence 
of Fyn was unaffected by LKB1 co-expression (Figure 
2C, 2D, 2E). These data demonstrate that Fyn-dependent 
tyrosine phosphorylation of AMPKα is independent of 
LKB1.
To demonstrate that AMPKα is a direct Fyn 
substrate, we incubated human purified AMPKα2 protein 
with purified Fyn-CA (Figure 2F). In the presence of 
ATP, Fyn was observed to robustly phosphorylate the 
AMPKα2 subunit. The specificity for Y436 was confirmed 
by expression of the Y436F AMPKα mutant (Y436F-
AMPKα2-Flag) with V5-FynCA in HeLa cells. As readily 
apparent in Figure 2G and 2H, the ability of V5-Fyn-
CA to tyrosine phosphorylate the Y436F AMPKα2-Flag 
mutant was reduced compared to WT AMPKα2-Flag, 
demonstrating that Fyn specifically phosphorylates 
AMPKα2 on Y436.
Tyrosine phosphorylation of the AMPK α2 
subunit residue Y436 inhibits AMPK activity
To evaluate whether tyrosine phosphorylation on 
Y436 has an effect on AMPK activity, we silenced the 
endogenous AMPK α1 and α2 subunits in HEK293T 
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Figure 1: Fyn phosphorylates AMPKα in skeletal muscle. A. Whole cell lysates from gastrocnemius muscle of either FynKO 
mice, WT, HSA-FynB (FynB) or HSA-FynT (FynT) mice were homogenized and immnoblots were performed by AMPKα mAb and 
GAPDH B. Gastrocnemius muscle of either FynKO mice, WT, HSA-FynB (FynB) or HSA-FynT (FynT) mice were homogenized 
and immunoprecipitated with 4G10 mAb followed by immunoblotting with AMPK mAb. Blots are representative of 3 independent 
experiments. C. Signal quantification of tyrosine-phosphorylated AMPKα levels from (A) and (B). Statistical examination between each 
set was performed. ***P < 0.005.
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Figure 2: Fyn phosphorylates AMPK on tyrosine 436. A.,  B. NIH3T3 cells were co-transfected with 3myc-AMPKα2-Flag 
and Fyn-CA-V5. 48 h later, cells extracts were prepared and immunoprecipitated with a Flag antibody. Immunoblots of lysates (A) and 
immunoprecipitation samples (B) were performed with the indicated antibodies. Blots are representative of 3 independent experiments. 
C., D. Forty-eight hours after co-transfection with 3myc-AMPKα2-Flag, Fyn-CA-V5 and pcDNA3-LKB1, HEK293T cells extracts were 
prepared and immunoprecipitation was performed using a Flag antibody. Immunoblots of lysates (C) and immunoprecipitation samples 
(D) were performed with the indicated antibodies. These are representative immunoblots independently performed 3 times. E. Signal 
quantification of tyrosine-phosphorylated AMPKα levels from (D). Statistical examination between each set was performed. F. Purified 
Human PRKAA2 (100 ng) and either mock or Flag-Fyn-CA (380 ng) were incubated with the kinase buffer and ATP at 30oC for 30 min. 
Samples were boiled and separated onto a 8% SDS-PAGE gel, followed by immunoblotting with the indicated antibodies. G., H. HeLa 
cells were co-transfected by either 3myc-AMPKα2 WT or Y436F (YF) with Fyn-CA-V5. Immunoprecipitation was performed using a 
Flag antibody. Immunoblots of lysates (G) and immunoprecipitation samples (H) were performed with the indicated antibodies. Images are 
representative of 4 independent experiments. 
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cells using specific human siRNA. As shown in Figure 
3A, siRNA-mediated knockdown of AMPKα greatly 
reduced endogenous AMPKα protein expression levels. 
The knockdown cells were then transfected with an 
empty vector (pcDNA3), rat GST-AMPKα1-WT (WT) 
or the GST-AMPKα1-Y430F mutant (the equivalent to 
human Y436 of AMPK α2 subunit (Y436F)). We selected 
these rat constructs as they are not affected by human 
AMPKα siRNA and therefore continue to be expressed 
in HEK293T cells transfected by human AMPKα siRNA. 
Phosphorylation of acetyl-CoA carboxylase (ACC) on 
S79 (pS79-ACC), the specific AMPK site on ACC [34, 
35] was used as a read-out for AMPK activity. As apparent 
in Figure 3B and 3C, siRNA mediated knockdown of 
endogenous AMPK reduced the basal level of pS79-
ACC. Re-expression of rat GST-AMPKα1-WT resulted 
in a relatively small but significant increase in pS79-
ACC whereas re-expression of rat GST-AMPKα1-Y430F 
increased ACC phosphorylation to a greater extent. 
The relative weak effect of rat GST-AMPKα1-WT to 
reconstitute AMPK dependent ACC phosphorylation was 
likely due to either the use of rat GST-AMPKα1 fusion 
protein or it might be that the rat protein does not fully 
compliment the human α1 subunit in HEK293T cells. 
Nevertheless, these data demonstrate that the Y436F 
AMPKα mutant displays significantly more AMPK 
activity than WT-AMPKα. 
Recently, studies have demonstrated that AMPK 
kinase activity is regulated by modification of the AMPK 
α, β, γ subunit trimeric complex assembly state [14, 15, 
17]. To determine whether Fyn suppresses AMPK activity 
through dissociation of the α, β, γ subunit interactions, 
we performed a series of co-immunoprecipitation 
experiments (Figure 3D, 3E and supplementary Figure 
2A and 2B). Co-immunoprecipitation analyses revealed 
that phosphorylation of AMPK Y436 had no effect on the 
assembly status of the AMPK trimeric complex, indicating 
that Fyn-dependent phosphorylation and inhibition of 
AMPK activity does not result from AMPK subunit 
dissociation.
Prolonged TNFα treatment diminishes AICAR-
dependent AMPK activation through Fyn
Although a number of studies have shown that 
the pro-inflammatory cytokine TNFα regulates AMPK 
activity [10, 29], the molecular mechanisms underlying 
this regulation are still unclear [10, 29, 31, 32]. To test 
the hypothesis that TNFα might regulate AMPK through 
Fyn-dependent phosphorylation, we first examined acute 
and prolonged effects of TNFα incubation on AMPK T172 
phosphorylation levels.
Short term (12 h) of TNFα treatment enhanced 
both basal and AICAR-stimulated T172 AMPKα 
phosphorylation levels (Figure 4A and 4B). In contrast, 
while prolonged incubation with TNFα (24-36 h) 
still enhanced T172 phosphorylation levels in basal 
condition, additional AICAR-dependent phosphorylation 
was abolished. Similarly, AICAR-dependent ACC 
phosphorylation was also further enhanced by TNFα 
treatment at 12 h but not at 24 or 36 h (Figure 4A and 4C). 
TNFα treatment also enhanced Fyn kinase activity in a cell 
extract assay (Figure 5A), without any significant change 
in Fyn protein levels (Figure 5B). Moreover this was 
associated with increased endogenous AMPKα subunit 
tyrosine phosphorylation (Figure 5C and 5D).
To further investigate the role of Fyn in relaying 
the effects of TNFα on AMPKα phosphorylation, we next 
silenced Fyn protein expression by siRNA in HEK293T 
cells. As shown in Figure 6, AICAR increased AMPKα 
phosphorylation (Figure 6A and 6B) and subsequent ACC 
phosphorylation (Figure 6A and 6C) in non-target siRNA 
transfected HEK293T cells. Prolonged TNFα treatment 
increased the basal state of AMPKα phosphorylation but 
not that of ACC, suggesting that despite the increase of 
T172 phosphorylation, AMPK activity was not optimal. 
Additionally, neither AMPKα nor ACC phosphorylation 
levels were increased following AICAR stimulation, 
demonstrating that chronic TNFα blunts the effect of 
AICAR. However, AMPK and ACC phosphorylation 
levels were restored and increased in Fyn knockdown 
cells, suggesting that lack of Fyn the HEK293T cells 
prevented TNFα inhibition of AICAR-stimulated AMPKα 
T172 phosphorylation and activation. 
Fyn regulates autophagy through AMPK 
phosphorylation to regulate apoptosis
As AMPK plays an important regulatory function 
in the control of autophagy [1, 36], we next examined 
the role of Fyn-dependent AMPK regulation in this 
process. For this, HEK293T cells in which endogenous 
AMPK α1 and α2 subunits were silenced (as in Figure 
3) were transfected with the empty vector (pcDNA3), 
GST-AMPKα-WT (WT) or the GST-AMPKα1-Y430F 
mutant (the equivalent to human Y436 of AMPK α2 
subunit (Y436F)). ULK1 phosphorylation on the AMPK 
activating site was then quantified [12, 13]. GST-AMPK-
WT expression increased ULK1 phosphorylation and 
expression of the rat GST-AMPK-Y430F mutant resulted 
in a further increase (Figure 7A). We next examined the 
effect of Fyn knockdown on ULK1 phosphorylation 
levels in basal, AICAR-stimulated and prolonged TNFα 
stimulated cells (Figure 7B and 7C). AICAR significantly 
increased ULK1 phosphorylation indicating that 
autophagy was up regulated, and TNFα blunted this effect. 
Importantly siRNA mediated knockdown of Fyn prevented 
the chronic TNFα inhibition of AICAR-stimulated 
ULK1 phosphorylation (Figure 7B and 7C). In line with 
this, AICAR increased the ratio of LC3-II/LC3-I and 
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Figure 3: AMPK activity is decreased by tyrosine phosphorylation. A. HEK293T cells were co-transfected with human 
siAMPK α1 and α2 subunits and either empty vector (pcDNA3), GST-rat AMPKα WT (WT) or Y430F mutant (equivalent to human 
Y436F (Y436F)) that are not affected by human AMPKa siRNA. 72 h after transfection immunoblots were performed with the indicated 
antibodies. B., C. S79 phosphorylation of ACC and total ACC levels in samples from (A) were assessed (B) and signal quantification of the 
expression levels of S79 phosphorylation of ACC normalized with total ACC were performed (C). Statistical examination between each sets 
were performed *p < 0.05, ***p < 0.005. D., E. HEK293T cells were transfected by either 3myc-AMPKα2 WT or Y436F-Flag (Y436F). 
Co-immunoprecipitation was performed by either control IgG or AMPK β1/β2 polyclonal antibody. Immunoblots of lysates (D) and 
immunoprecipitation samples (E) were performed with the indicated antibodies. Images are representative of 3 independent experiments.
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Figure 4: Prolonged TNFα stimulation suppresses AICAR dependent AMPK activation. A. HEK293T cells were incubated 
with TNFα (10 ng/ml) for 12, 24 or 36 h and then stimulated with 2 mM AICAR for 10 min. Immunoblots were performed with the 
indicated antibodies. These are representative images from 3 independent experiments. B., C. Signal quantifications of expression levels 
of phospho- T172 AMPKα corrected by total AMPKα (B) and levels of phospho- S79 of ACC to total ACC (C). The data are presented as 
mean ± s.e.m. Statistical examination between control and AICAR stimulated cells in each sets were performed. **p < 0.01, ***p < 0.005.
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Figure 5: Prolonged TNFα stimulation up-regulates Fyn activity in HEK293T cells. A. Fyn kinase activity in HEK293T 
cells treated or not with TNFα (10ng/ml) for 36 h. These are representative images from 5 independent experiments ***p < 0.005. B. 
Fyn expression in HEK293T cells treated or not with TNFα for 36 h. C. After a 36-h incubation with 10ng/ml TNFα, HEK293T cells 
were treated or not with TNFα for 36 h and homogenized. Immunoprecipitation was performed with total AMPKα antibody followed by 
immunoblotting with the 4G10 and total AMPKα antibody. These are representative images from 4 independent experiments. D. Signal 
quantification (Y436 normalized to total AMPKα) from (C). (***P < 0.005)
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Figure 6: TNFα regulates AICAR-dependent AMPK activation via Fyn kinase. A. HEK293T cells were transfected with Fyn 
siRNAs. Cells were treated with TNFα (10 ng/ml) for 36 h with or without 2 mM AICAR for 10 min. Immunoblots were performed with 
the indicated antibodies. These are representative images from 3 independent experiments. B., C. Signal quantifications of expression levels 
of phospho- T172 AMPKα normalized to total AMPKα (B) and levels of S79 phosphorylation of ACC normalized to total ACC (C). The 
data are presented as mean ± SE. Statistical examination between control and AICAR stimulated cells in each sets were performed. *P < 
0.05, **P < 0.01.
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decreased expression of p62, consistent with an increase 
in autophagic activity (Figure 8A, 8B and 8C). While this 
was blunted when cells were treated with TNFα, siRNA-
mediated knockdown of Fyn prevented this chronic TNFα 
inhibition of AICAR-stimulated autophagy activation. 
AICAR is an adenosine analog that directly modulates 
AMPK activity, and these results suggested the direct 
TNFα-Fyn regulation of the AMPK-autophagy axis. To 
confirm that Fyn mediates autophagy via AMPK we next 
took advantage of metformin, a known AMPK activator 
that is also an autophagy inducer. As shown Figure 8D, 
8E and 8F, metformin increased the ratio of LC3-II/LC3-I 
and decreased p62 in the basal state, which is consistent 
with an increase in autophagic activity. Again, while this 
was blunted when cells were treated with TNFα, siRNA-
mediated knockdown of Fyn prevented this chronic TNFα 
inhibition of metformin-stimulated autophagy activation 
(Figure 8D, 8E and 8F).
To confirm these results, we utilized the GFP-
LC3 puncta formation assay. As shown Figure 9A, 9B 
and supplementary Figure 3A, AICAR increased the 
number of puncta in each cell, which is consistent with an 
increase in autophagic activity. While TNFα suppressed 
the AICAR induction of GFP-LC3 puncta, this was 
essentially completely reversed by siRNA-mediated 
knockdown of Fyn (Figure 9A, 9B and supplementary 
Figure 3A). While GFP-LC3 puncta formation assay 
indicates the levels of LC3 lipidation, it is not always 
correlated with the increase of autophagy flow. To 
confirm our results, we utilized the lysosomotrophic 
agent Bafilomycin A1 to inhibit the autophagy flow. As 
shown Figure 9C, 9D and supplementary Figure 3C and 
3D, Bafilomycin A1 treatment significantly increased 
GFP-LC3 puncta formation in the basal state and AICAR 
accelerated this process, indicating that even in basal state 
the HEK293T cells have a certain level of autophagy flow 
that is increased by AICAR. Importantly Bafilomycin 
A1 was unable to increase GFP-LC3 puncta in the 
absence or presence of AICAR in TNFα-treated cells. In 
contrast, siRNA-mediated knockdown of Fyn restored 
the autophagy flow in the TNFα-treated cells both in 
the absence and presence of AICAR (Figure 9C, 9D and 
supplementary Figure 3B and 3C). 
Since prolonged exposure of inflammatory 
mediators inhibit autophagy resulting in severe cell 
damage and apoptosis [10], we next examined the role of 
Fyn in apoptosis. As shown Figure 10A and 10B, AICAR 
did not change the basal state level of apoptosis reflected 
by PARP cleavage. This lack of AICAR protection is likely 
due to a limited basal apoptotic response in HEK293T 
cells, a fact that we confirmed as we were unable to detect 
CHOP induction in these cells (not shown). However 
under these conditions, TNFα slightly induced PARP 
cleavage, which was rescued by AICAR, indicating that 
TNFα-induced apoptosis could be regulated by AMPK. 
Interestingly siRNA-mediated knockdown of Fyn 
resulted in a complete loss of PARP cleavage indicating 
that apoptosis was completely blocked (Figure 10A and 
10B). These data indicate that TNFα-induced apoptosis 
might partially be regulated by AMPK through Fyn, 
although our data also suggest that Fyn regulates apoptosis 
independently of AMPK.
DISCUSSION
AMPK is a master energy sensor in cells and it 
is activated in various conditions where cellular ATP is 
decreased. AMPK also has a major role in pathological 
conditions (e.g. metabolic syndrome, cancer, Alzheimer’s 
disease) and therapeutic activation of AMPK is believed to 
have beneficial advantages for several disease processes. 
For example, metformin increases AMPK activity and is 
the most commonly prescribed oral anti-diabetic agent 
[34, 35] and recent studies have also shown that metformin 
therapy decreases cancer risk [37]. 
AMPK is a heterotrimeric complex composed of 
three different subunits α, β, γ and currently only two 
AMPK kinases (LKB1 and CaMKK2) and two AMPK 
phosphatases (PP2A and PP2C) are known to regulate 
AMPK activity [17, 18, 38, 39]. AMPK regulation 
is mainly affected by the tissue distribution of these 
upstream kinases. For example, LKB1 is expressed in 
peripheral tissues (liver, skeletal muscle and adipose) 
while CaMKK2 is present in neuronal cells [40, 41]. We 
identified one member of the Src family of proto-oncogene 
non-receptor tyrosine kinases, Fyn that regulates AMPK 
activity in peripheral tissues by directly interacting with 
LKB1 [21]. 
In this study, we now demonstrate that Fyn 
also directly regulates AMPK. We found that Fyn 
phosphorylates the AMPK α subunit on Y436 and this 
phosphorylation suppresses AMPK activity. The AMPK 
α subunit is composed of a kinase domain (KD) and a 
regulatory C-terminus. The regulatory C-terminus has 
an auto-inhibitory domain (AID), a sensor (αRIM) loop 
and a β-subunit interaction domain (β-ID). Additionally, 
a recent publication has implicated that AMP binding to 
CBS-3 of γ subunit induces the interaction of AID-αRIM2 
and γ unit resulting in AMPK activation by releasing 
AID inhibition of the kinase domain [42]. Interestingly, 
inspection of AMPK sequence revealed that Y436 is 
localized in β-ID immediately after the αRIM-2 that is 2nd 
part of αRIM and interacting with AID. This suggested 
that Y436 phosphorylation could affect AMPK subunits 
assembly. However, we found that Y436-dependent 
inhibition of AMPK activity was not due to the assembly 
state of the AMPK heterotrimeric complex (Figure 3C, 3D 
and supplementary Figure 2A, 2B) and since there is no 
change in the binding affinity between α subunit and β 
subunit by tyrosine phosphorylation of AMPK α subunit, 
we speculate that phosphorylation of Y436 may modify 
the AID-αRIM2 interaction. 
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Figure 7: Fyn-mediated AMPK regulation inhibits ULK1 phosphorylation. A. HEK293T cells were co-transfected with 
siRNAs of human siAMPK α1 and α2 subunits and either empty vector (pcDNA3), GST-rat AMPKα WT (WT) or Y430F mutant (equivalent 
to human Y436F (Y436F)) to be replaced. Immunoblots were performed 72 h after transfection. B. HEK293T cells were transfected with 
Fyn siRNAs. Cells were treated with 10ng/ml TNFα for 36 h with or without 2 mM AICAR for 10 min. Immunoblots were performed 
with the indicated antibodies. These are representative images from 3 independent experiments. C. Signal quantifications of the expression 
levels of phospho-S555 ULK1 to total ULK1. The data are presented as mean ± SE. Statistical examination between control and AICAR 
stimulated cells in each sets were performed *P < 0.05, **P < 0.01.
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Figure 8: Fyn regulates metabolic stress- induced autophagy through AMPK. A. HEK293T cells were transfected with 
siRNA for Fyn. The cells were treated with 10 ng/ml TNFα for 36 h with or without 2 mM AICAR for 10 min and immunoblots were 
performed with the indicated antibodies. These are representative images independently performed 3 times. B., C. Signal quantifications of 
the ratio of LC3-II to LC3-I (B) and p62/GAPDH (C). The data are presented as mean ± s.e.m. Statistical examination between control and 
AICAR stimulated cells in each sets were performed **P < 0.01, ***P < 0.005 D. HEK293T cells were transfected with siRNA for Fyn. 
Cells were treated with 10 ng/ml TNFα for 36 h with or without 5 mM Metformin for 20 min and immunoblots were performed with the 
indicated antibodies. These are representative images independently performed 3 times. E., F. Signal quantifications of the ratio of LC3-II 
to LC3-I (E) and p62/GAPDH (F). The data are presented as mean ± s.e.m. Statistical examination between control and AICAR stimulated 
cells in each sets were performed **P < 0.01, ***P < 0.005.
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Figure 9: GFP-LC3 puncta formation assay confirms Fyn’s regulation of AICAR dependent autophagy. A. HEK293T 
cells were transfected with both siRNA for Fyn and GFP-human LC3 construct. The cells were treated with 10 ng/ml TNFα for 36 h with 
or without 2 mM AICAR for 10 min. Cells were fixed with 4% paraformaldehyde and mounted with DAKOCytomation Fluorescent 
Mounting Medium (S3023). These are representative images of high power field from experiments independently performed 3 times. B. 
Number of puncta in each single cell. Data are representative of n = 5 experiments. Statistical examination between control and AICAR-
stimulated cells in each sets were performed ***P < 0.005. C. HEK293T cells were transfected with both siRNA for Fyn and GFP-human 
LC3 construct. Cells were treated with 10 ng/ml TNFα for 36 h with or without 100 nM Bafilomycin for 4 h and 2 mM AICAR for 10 
min. Cells were fixed with 4% paraformaldehyde and mounted with DAKOCytomation Fluorescent Mounting Medium (S3023). These 
are representative images of high power field from experiments independently performed 3 times. D. Number of puncta in each single 
cell. Data are representative of n = 5 experiments. Statistical examination between control and AICAR stimulated cells in each sets were 
performed ***P < 0.005.
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 Utilizing TNFα, a pro-inflammatory cytokine, 
we next examined the role of Fyn regulation of AMPK 
under metabolic stress conditions. Recent studies have 
reported that TNFα infusion into lean animals increases 
PP2C expression, resulting in a reduction in AMPK 
signaling, fatty acid oxidation, and the development 
of skeletal muscle insulin resistance [28, 30], but acute 
incubation of TNFα regulated AMPK activity due to 
a reduction in the AMP/ATP ratio at least in 3T3L1 
adipocytes and in the epithelium-lymphocyte co-culture 
state [31, 32]. Therefore we examined the chronic effect 
of low grade-prolonged TNFα stimulation, which is more 
likely to reflect in vivo patho-physiological conditions. 
As expected, prolonged incubation of TNFα suppressed 
AICAR stimulated T172 α subunit phosphorylation 
and subsequent ACC phosphorylation, indicating 
that prolonged TNFα desensitized AMPK activation. 
Additionally, we demonstrated that under these conditions 
Fyn was activated and AMPK was phosphorylated on 
Y436, suggesting that this desensitization directly results 
from the Fyn-dependent tyrosine phosphorylation of 
the AMPK α subunit. Moreover we found that Fyn also 
regulated AICAR-dependent AMPK activation under 
prolonged TNFα stimulation. 
Recent studies have implicated that AMPK 
regulates autophagy through a direct AMPK-dependent 
phosphorylation of ULK1 [12, 13] therefore we assessed 
this as a relevant physiological output. Our data further 
demonstrate that Fyn-dependent suppression of AMPK 
activity results in the inhibition of ULK1 phosphorylation 
and subsequent activation of autophagy, indicated by a 
induction in the formation of LC3-II, increase in the LC3-
II/LC-I ratio, decreased p62 expression, GFP-LC3 puncta 
formation and autophagic flow.
Figure 10: Fyn regulates metabolic stress- induced PARP cleavage through AMPK. A. HEK293T cells were transfected with 
siRNA for Fyn and treated with 10 ng/ml TNFα for 36 h with or without 2 mM AICAR for 10 min. 150 µg of Lysate were immunoblotted by 
cleaved PARP pAb (#5625, Cell Signaling) and GAPDH mAb. These are representative images from experiments independently performed 
3 times. B. Signal quantifications of cleaved PARP/GAPDH. The data are presented as mean ± s.e.m. Non-identical letters (a, b and c) 
indicate results that are statistically different from each other at p < 0.05.
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Since autophagy induction by AMPK activation 
rescues cells from cell death [11], we examined PARP 
cleavage and demonstrated that TNFα induction of 
apoptosis is inhibited by AICAR. More importantly when 
Fyn was knockdown, apoptosis was completely blocked 
indicating that AMPK regulates TNFα-induced apoptosis 
and that Fyn plays a significant role in this process. 
However, since autophagic activity was not affected 
in Fyn knockdown cells and apoptosis was not induced 
suggest the presence of alternative pathways autophagy 
regulating apoptosis by Fyn.
In summary, we found that Fyn directly 
phosphorylates the α subunit of AMPK on Y436 and this 
phosphorylation suppresses AMPK activity, subsequently 
resulting in increased ACC and ULK1 phosphorylation. 
Prolonged exposure to pro-inflammatory cytokines such 
as TNFα decreased AICAR-dependent AMPK activation 
through activation of Fyn. These modulatory events 
manifest in the inhibition of AMPK-dependent autophagy 
activation and subsequent apoptosis, suggesting that 
targeting Fyn activity may have positive therapeutic 
potential as a novel pathway to activate AMPK.
EXPERIMENTAL PROCEDURES
Antibodies and reagents
Flag antibody was from Sigma-Aldrich (St. 
Louis, MO, USA), the 4G10 and GST antibodies were 
from Millipore (Bilerica, MA, USA), GAPDH and V5 
antibodies were purchased from MBL (Woods Hole, MA, 
USA), Fyn antibody was from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA), LC3 antibody was from Novus 
Biologicals (Littleton, CO, USA) and p62 antibody was 
from Enzo Life sciences (Exeter, UK). All other antibodies 
were purchased from Cell Signaling (Boston, MA, USA). 
Bafilomycin A1 and AICAR were from Sigma-Aldrich 
(St. Louis, MO, USA). TNFα and Metformin were from 
EMD Millipore (Bilerica, MA, USA), Toronto Research 
Chemicals (Toronto, Ontario, Canada) and Cayman 
Chemical (Ann Arbor, MI, USA) respectively. Leupeptin 
Hemisulfate was from Fisher Scientific (Pittsburgh, PA, 
USA). DharmaFECT Duo Transfection Reagent and 
siRNAs for AMPKα1, α2 and Fyn were purchased from 
GE Healthcare (Little Chalfont, UK). X-tremeGENE 
HP DNA Transfection Reagent were from Roche (Basel, 
Switzerland). All other reagents were purchased from 
Sigma-Aldrich.
cDNA constructs
The pCMV6 Entry Myc-DDK tagged ORF 
clone of Homo sapiens AMPK α2 construct was 
obtained from Origene (Rockville, MD, USA) and 
used to generate the pCMV6-3Myc-2-AMPKα2-
Myc DDK construct. The gene encoding AMPK 
α2 was amplified with the oligonucleotides: 
5’- GAATTCGCCCGGGCGGGATCCCCCG 
GGCTGCAGATGGCTGAGAAGCAGAAGCA-3’ and 
5’- AAGCTTGGTACCGGGCCCCCCCTCGAGGTCGA 
CGGTATCGATAACCTTATCGTCGTCATCCT-3’ 
and cloned to pCR-BluntII-TOPO (Invitrogen, CA, 
USA). This construct and pCMV-3Myc-2 (Agilent 
Technologies, Santa Clara, CA, USA) were digested with 
EcoRI and HindIII to obtain pCMV-3Myc-2-AMPKα2-
Myc-DDK. GST-AMPKα1(r), pcDNA3, pcDNA3-
Fyn-CA, pcDNA3-LKB1 and eGFP-hLC3 construct 
were constructed or obtained before [21]. Human 
Y436 of AMPK α2 subunit is equivalent to rat Y430 
of AMPKα1. Y430F of GST-AMPKα1 was obtained 
by QuickChange 2-XL Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA, USA) 
with the pair of oligonucleotides: 5’- GGAAGGT 
TGTAAACCCCTTTTATTTGCGTGTGCGAAG-3 
and 5’- CTTCGCAC 
ACGCAAATAAAAGGGGTTTACAACCTTCC-3’ 
Animals
Mice over expressing the murine FynB and FynT 
cDNA were established as previously described [27]. 
pp59fyn knockout mice and their controls were obtained 
from The Jackson Laboratory (Bar Harbor, ME, USA). 
Animals were housed in a facility equipped with a 12 h 
light/dark cycle and fed ad libitum a standard chow diet 
(Research Diets, New Brunswick, NJ) containing 67% 
(Kcal) carbohydrates, 19% protein, and 4% fat. All studies 
were approved by and performed in compliance with the 
guidelines of the Albert Einstein College of Medicine 
Institutional Animal Care and Use Committee (IACUC).
Cell culture
HEK293T, NIH3T3 and HeLa cells (ATCC, 
Manassas, VA, USA) were cultured in Dulbecco’s 
Modified Eagle’s Medium (Invitrogen, CA, USA) with 
10% Fetal Bovine Serum (Atlanta Biologicals, Flowery 
Branch, GA, USA) and 1% Penicillin-Streptomycin (Life 
technologies, Norwalk, CT, USA). Cells were incubated 
at 37°C moisturized incubator with 5% CO2. DNA 
Transfection was performed using X-tremeGENE HP 
DNA Transfection Reagent and siRNA transfection was 
performed using DharmaFECT Duo Transfection Reagent 
according to the manufacture’s instructions. siGENOME 
Human AMPK α1 and α2 and FYN siRNA SMART pool 
and Non-target siRNA were from GE Healthcare. We saw 
the effect of AICAR mediating AMPK phosphorylation 
and activity was fully regulated under confluent condition 
in HEK293T cells, so every experiments with HEK293T 
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cells were performed under confluent cells condition.
Western blot analysis
Tissues and cell extracts were prepared as described 
before [27]. Briefly, homogenates were centrifuged for 30 
min at 14,000 rpm at 4°C, and supernatants were collected. 
Protein concentration was determined with the BCATM 
Protein Assay (Thermo Scientific, Rockford, IL). Protein 
lysates (40 µg) were separated on 8 to 15% reducing 
polyacrylamide gels and transferred onto Immobilon-P 
polyvinylidene difluoride membranes. Immunoblots were 
blocked with 5% milk in Tris-buffered saline or Odyssey 
Bocking Buffer (Li-COR Biotechnology, Lincoln, NE) 
for 60 min at room temperature and incubated overnight 
at 4°C with the indicated antibodies in Tris-buffered 
saline and 0.05% Tween 20 (TBST) containing 1% 
BSA. Blots were washed in TBST and incubated with 
horseradish peroxidase-conjugated secondary antibodies 
(1:30,000) for 30 min at room temperature. Membranes 
were washed in TBST, and antigen-antibody complexes 
were visualized by chemiluminescence using an ECL kit 
(Pierce). Alternatively, immunoblots were incubated with 
IRDye800CW Goat Anti Mouse (H+L) or IRDye680 Goat 
Anti Rabbit (H+L) secondary antibodies and signal was 
detected with the Odyssey Infrared Imaging System (Li-
COR Biotechnology).
Immunoprecipitation
Protein from cells and tissues were prepared in a 
buffer containing 50mM Tris (pH 7.4), 1% glycerol and 
1% NP40 supplemented with protease inhibitor (Complete 
mini, Roche Pharmaceuticals, Nutley, NJ). Homogenates 
were centrifuged for 30 min at 14,000 rpm at 4°C, and 
supernatants were collected. Protein concentration was 
determined with the BCATM Protein Assay. Lysates (5-6 
mg) were immunoprecipitated with indicated antibodies 
followed by incubation with ProteinA/G plus. Samples 
were washed 3 times and boiled and separated onto 10% 
SDS-PAGE followed by an overnight transfer. Western 
blot analysis was performed with the indicated antibodies. 
Alternatively, immunoprecipitation was performed with 
Catch and Release® v2.0 Reversible Immunoprecipitation 
System (EMD Millipore) according to manufacturer’s 
protocol, followed by immunoblotting with the indicated 
antibodies.
In vitro AMPK phosphorylation assay
AMPKα2 subunit fusion protein and FynT was 
purchased from Abnova and BPS bioscience, respectively. 
AMPKα2 protein (1 µg) was incubated with the 
recombinant FynT kinase active (1.8U) in presence of 
ATP and kinase buffer (Cell Signaling) and kinase reaction 
was performed for 1 h at 35oC. Samples were separated on 
10% SDS-polyacrylamide gels and immunoblotting was 
performed with 4G10 monoclonal antibody. 
Fyn activity assay
Fyn activity assay was performed with Universal 
Tyrosine Kinase Assay kit (Takara Bio Inc, Shiga, Japan) 
as described previously [27]. Briefly, homogenates were 
prepared and protein concentration was determined 
by BCA method. Samples (0.5-1 mg) were incubated 
with 4 µg of Fyn rabbit polyclonal antibody (Santa 
Cruz Biotechnology) coupled with Catch and Release® 
v2.0 Reversible Immunoprecipitation System (EMD 
Millipore). Samples were washed three times with NP-
40 lysis buffer and once with the kinase reaction buffer. 
Immuno-complexes were diluted 2.5 fold and 40 µl 
samples and 10 µl ATP solution were incubated in an 
ELISA plate provided. Measurement of the kinase activity 
was performed according to the manufacturer’s protocol.
Immunofuorescence
HEK293T cells were transfected with GFP-human 
LC3 construct. Transfected cells were washed with PBS 
and fixed for 10 min in PBS containing 4% PFA. Cells 
were imaged using a confocal fluorescence microscope 
(FV10i; Olympus). 
Statistics
All data are presented as mean ± s.e.m. Significant 
data were defined as p < 0.05 using Student’s t test or 
ANOVA. 
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